Overview Dividends

(ACAD) ACADIA Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0042251084

Antipsychotic, Rett, Schizophrenia, Tremor, Depression

Biotechnology
Market Cap in USD: 4,715m

IPO / Inception: 2004-05-27
Return 12m vs S&P 500: 35.4%

EPS (Earnings per Share)

EPS CAGR: 57.52%
EPS Trend: 77.1%

Last SUE: 1.27
Qual. Beats: 1

Revenue

Rev. CAGR: 22.35%
Rev. Trend: 92.8%

Last SUE: 0.22
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	47.0%
Value at Risk 5%th	63.2%
Relative Tail Risk	-18.17%

Reward TTM
Sharpe Ratio	1.08
Alpha	39.63
CAGR/Max DD	0.28

Character TTM
Hurst Exponent	0.573
Beta	0.868
Beta Downside	0.886

Drawdowns 3y
Max DD	57.87%
Mean DD	31.87%
Median DD	33.45%

Description: ACAD ACADIA Pharmaceuticals November 09, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) is a U.S.-based biopharma focused on central nervous system (CNS) disorders and rare diseases, commercializing NUPLAZID (pimavanserin) for Parkinson’s disease psychosis and developing a pipeline of novel agents across schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, essential tremor, treatment-resistant depression, Rett syndrome, and Fragile X.

NUPLAZID generated $215 million in 2023 revenue, representing roughly 70 % of ACAD’s total sales, and the drug benefits from a 10-year orphan exclusivity period that underpins a stable cash flow in a niche market.

The pipeline’s most advanced candidates include pimavanserin for negative-symptom schizophrenia (Phase III completed), ACP-101 for hyperphagia in Prader-Willi syndrome (Phase III completed), and ACP-204 for Alzheimer’s disease and Lewy-body dementia psychosis (Phase II completed); collectively these address indications with an estimated addressable market of >$8 billion in the U.S. alone.

As of the latest 10-Q, ACAD held $450 million of cash and marketable securities, giving it roughly 18 months of runway at current burn rates; R&D expense averaged $120 million annually, reflecting a heavy investment in late-stage trials.

The CNS biotech sector is being propelled by an aging population, rising prevalence of neurodegenerative disorders, and favorable regulatory pathways for rare-disease therapies, all of which create a supportive macro environment for ACAD’s focus areas.

For a deeper, data-driven assessment of ACAD’s valuation and risk profile, you may find the analytics on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (261.2m TTM) > 0 and > 6% of Revenue (6% = 62.8m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA -5.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 68.74% (prev 47.82%; Δ 20.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 198.9m <= Net Income 261.2m (YES >=105%, WARN >=100%)

Net Debt (-203.2m) to EBITDA (117.3m) ratio: -1.73 <= 3.0 (WARN <= 3.5)

Current Ratio 3.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (170.7m) change vs 12m ago 2.69% (target <= -2.0% for YES)

Gross Margin 91.92% (prev 91.61%; Δ 0.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 90.75% (prev 95.12%; Δ -4.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -0.61 (EBITDA TTM 117.3m / Interest Expense TTM -170.4m) >= 6 (WARN >= 3)

Altman Z'' -6.26

(A) 0.54 = (Total Current Assets 1.08b - Total Current Liabilities 356.6m) / Total Assets 1.33b

(B) -1.57 = Retained Earnings (Balance) -2.09b / Total Assets 1.33b

warn (B) unusual magnitude: -1.57 — check mapping/units

(D) -5.04 = Book Value of Equity -2.09b / Total Liabilities 413.5m

Total Rating: -6.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.06

1. Piotroski 3.0pt

2. FCF Yield 5.04%

3. FCF Margin 18.89%

4. Debt/Equity 0.06

5. Debt/Ebitda -1.73

6. ROIC - WACC (= 72.09)%

7. RoE 32.27%

8. Rev. Trend 92.81%

9. EPS Trend 77.12%

What is the price of ACAD shares?

As of December 31, 2025, the stock is trading at USD 26.70 with a total of 1,048,061 shares traded.
Over the past week, the price has changed by -4.06%, over one month by +7.44%, over three months by +25.23% and over the past year by +59.98%.

Is ACAD a buy, sell or hold?

ACADIA Pharmaceuticals has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy ACAD.

Strong Buy: 7
Buy: 6
Hold: 6
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the ACAD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	29.8	11.6%
Analysts Target Price	29.8	11.6%
ValueRay Target Price	28.7	7.6%

ACAD Fundamental Data Overview December 27, 2025

Market Cap USD = 4.72b (4.72b USD * 1.0 USD.USD)
P/E Trailing = 17.9806
P/E Forward = 43.1034
P/S = 4.5029
P/B = 5.1403
P/EG = -0.42
Beta = 0.672
Revenue TTM = 1.05b USD
EBIT TTM = 103.2m USD
EBITDA TTM = 117.3m USD
Long Term Debt = 54.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 11.8m USD (from shortTermDebt, last quarter)
Debt = 54.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -203.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.92b USD (4.72b + Debt 54.8m - CCE 847.0m)
Interest Coverage Ratio = -0.61 (Ebit TTM 103.2m / Interest Expense TTM -170.4m)
FCF Yield = 5.04% (FCF TTM 197.8m / Enterprise Value 3.92b)
FCF Margin = 18.89% (FCF TTM 197.8m / Revenue TTM 1.05b)
Net Margin = 24.94% (Net Income TTM 261.2m / Revenue TTM 1.05b)
Gross Margin = 91.92% ((Revenue TTM 1.05b - Cost of Revenue TTM 84.6m) / Revenue TTM)
Gross Margin QoQ = 92.23% (prev 92.16%)
Tobins Q-Ratio = 2.95 (Enterprise Value 3.92b / Total Assets 1.33b)
Interest Expense / Debt = 16.55% (Interest Expense 9.07m / Debt 54.8m)
Taxrate = -60.96% (out of range, set to none) (-27.2m / 44.6m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 3.02 (Total Current Assets 1.08b / Total Current Liabilities 356.6m)
Debt / Equity = 0.06 (Debt 54.8m / totalStockholderEquity, last quarter 917.3m)
Debt / EBITDA = -1.73 (Net Debt -203.2m / EBITDA 117.3m)
Debt / FCF = -1.03 (Net Debt -203.2m / FCF TTM 197.8m)
Total Stockholder Equity = 809.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.63% (Net Income 261.2m / Total Assets 1.33b)
RoE = 32.27% (Net Income TTM 261.2m / Total Stockholder Equity 809.4m)
RoCE = 11.95% (EBIT 103.2m / Capital Employed (Equity 809.4m + L.T.Debt 54.8m))
RoIC = 81.19% (EBIT 103.2m / (Assets 1.33b - Curr.Liab 356.6m - Cash 847.0m))
WACC = 9.10% (E(4.72b)/V(4.77b) * Re(9.21%) + (debt cost/tax rate unavailable))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.24%
[DCF Debug] Terminal Value 65.36% ; FCFE base≈199.7m ; Y1≈131.1m ; Y5≈60.0m
Fair Price DCF = 5.79 (DCF Value 979.6m / Shares Outstanding 169.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 77.12 | EPS CAGR: 57.52% | SUE: 1.27 | # QB: 1
Revenue Correlation: 92.81 | Revenue CAGR: 22.35% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.12 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.81 | Chg30d=-0.006 | Revisions Net=+1 | Growth EPS=-1.2% | Growth Revenue=+11.3%

Additional Sources for ACAD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle